Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Central Hospital, Nancy, France: Clinical Trials & FDA Approval Profile

Central Hospital, Nancy, France (Global / Institutional) sponsors 20 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 9 active protocols (7 recruiting now), 2 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)5.0%
Median Closed Enrollment vs National (145 pts)14 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Central Hospital, Nancy, France
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)20
Active Pipeline (Recruiting Now)9 (7)
Completed vs Stopped Early2 / 1 (5.0%)
Median Closed Actual Enrollment14 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Central Hospital, Nancy, France
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07027020Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder DysfunctionPhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Central Hospital, Nancy, France Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI